Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
// Sona Pechackova 1, * , Kamila Burdova 1, * , Jan Benada 1 , Petra Kleiblova 1, 2 , Gabriela Jenikova 1 , Libor Macurek 1 1 Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, CZ-14220 Prague, Czech Republic 2 Institute of Biochemistry and Experimental Oncology, Charles University in Prague, CZ-12853 Prague, Czech Republic * These authors have contributed equally to this work Correspondence to: Libor Macurek, e-mail: libor.macurek@img.cas.cz Keywords: WIP1 inhibitor, p53, checkpoint, nutlin-3, breast cancer Received: October 31, 2015 Accepted: January 29, 2016 Published: February 13, 2016 ABSTRACT PP2C family serine/threonine phosphatase WIP1 acts as a negative regulator of the tumor suppressor p53 and is implicated in silencing of cellular responses to genotoxic stress. Chromosomal locus 17q23 carrying the PPM1D (coding for WIP1) is commonly amplified in breast carcinomas and WIP1 was proposed as potential pharmacological target. Here we employed a cellular model with knocked out PPM1D to validate the specificity and efficiency of GSK2830371, novel small molecule inhibitor of WIP1. We have found that GSK2830371 increased activation of the DNA damage response pathway to a comparable level as the loss of PPM1D . In addition, GSK2830371 did not affect proliferation of cells lacking PPM1D but significantly supressed proliferation of breast cancer cells with amplified PPM1D . Over time cells treated with GSK2830371 accumulated in G1 and G2 phases of the cell cycle in a p21-dependent manner and were prone to induction of senescence by a low dose of MDM2 antagonist nutlin-3. In addition, combined treatment with GSK2830371 and doxorubicin or nutlin-3 potentiated cell death through a strong induction of p53 pathway and activation of caspase 9. We conclude that efficient inhibition of WIP1 by GSK2830371 sensitizes breast cancer cells with amplified PPM1D and wild type p53 to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., & Toussaint, O. (2009) · Nature Protocols · doi:10.1038/nprot.2009.191 · Cited by 1,668
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
A role for ATR in the DNA damage-induced phosphorylation of p53
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development · doi:10.1101/gad.13.2.152 · Cited by 1,046
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · cited 1×
“RG7388, an orally available analogue of nutlin-3, efficiently suppressed tumor growth in vivo [47].”
BackgroundPPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
Lu, X., Nannenga, B., & Donehower, L. A. (2005) · Genes & Development · doi:10.1101/gad.1291305 · Cited by 389
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.
Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261
Cell fate decision mediated by p53 pulses
Zhang, X.-P., Liu, F., Cheng, Z., & Wang, W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813088106 · Cited by 253
MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin
Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198
Quantitative assay of senescence-associated β-galactosidase activity in mammalian cell extracts
Gary, R. K., & Kindell, S. M. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.06.003 · Cited by 195
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201210031 · Cited by 170 · cited 2×
“Evaluation of the cell cycle checkpoints was performed as described previously with minor modifications [39].”
BackgroundMethodSelf-citationThe role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168 · cited 1×
“com/oncotarget Transcriptional activity of the tumor suppressor p53 is regulated at multiple levels, including extensive phosphorylation in the transactivation and oligomerization domains and MDM2-dependent ubiquitination and degradation [67, 68].”
BackgroundRegulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140 · cited 1×
“Under basal conditions, function of the p53 is suppressed by an E3 ubiquitin ligase MDM2 and its enzymatically inactive homologue MDMX that control p53 stability and transcriptional activity, respectively [6, 7].”
BackgroundMüllers, E., Cascales, H. S., Jaiswal, H., Saurin, A. T., & Lindqvist, A. (2014) · Cell Cycle · doi:10.4161/15384101.2015.945831 · Cited by 84 · cited 1×
“Indeed, short activation of p53 during G2 triggered nuclear retention and subsequent degradation of Cyclin B1 and was sufficient to induce a permanent withdrawal from the cell cycle [77, 78].”
BackgroundLindqvist, A., de Bruijn, M., Macurek, L., Brás, A., Mensinga, A., Bruinsma, W., Voets, O., Kranenburg, O., & Medema, R. H. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.246 · Cited by 75 · cited 2×
“By inactivating the p53 pathway, WIP1 promotes recovery from the G2 checkpoint [17, 18].”
BackgroundPhosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response
Zhang, X., Lin, L., Guo, H., Yang, J., Jones, S. N., Jochemsen, A., & Lu, X. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0634 · Cited by 67
Role of Mdm4 in drug sensitivity of breast cancer cells
Lam, S., Lodder, K., Teunisse, A. F. A. S., Rabelink, M. J. W. E., Schutte, M., & Jochemsen, A. G. (2010) · Oncogene · doi:10.1038/onc.2009.522 · Cited by 52
The Wip1 phosphatase and Mdm2: cracking the “Wip” on p53 stability
Lu, X., Nguyen, T.-A., Zhang, X., & Donehower, L. A. (2008) · Cell Cycle · doi:10.4161/cc.7.2.5299 · Cited by 44
Cited by
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Sriraman, A., Radovanovic, M., Wienken, M., Najafova, Z., Li, Y., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9302 · Cited by 44
“In particular, the drug candidate GSK2830371 was shown to efficiently and specifically interfere with the phosphatase activity of Wip1 through allosteric inhibition [26].”
BackgroundResultInfluentialFortifying p53 – beyond Mdm2 inhibitors
Sriraman, A., Li, Y., & Dobbelstein, M. (2016) · Aging · doi:10.18632/aging.101073 · Cited by 6
Metadata
- Authors
- Pechackova, S., Burdova, K., Benada, J., Kleiblova, P., Jenikova, G., & Macurek, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-13
- Volume
- 7
- Issue
- 12
- Pages
- 14458-14475
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2276735096
- Cited by
- 75
- References
- 21
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.